» Argos Therapeutics' Arcelis Personalized Immunotherapy Platform In HIV Achieves Primary Endpoint In Phase 1 Trial
Argos Therapeutics announced the presentation of positive immune response data from a Phase 1 clinical trial of AGS-004 in HIV-infected adults in combination with antiretroviral therapy (ART)….